SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Home
/
update
/
details

SigTuple Secures $4 Million in Extended Series C Funding Led by SIDBI Venture Capital

NextEdge Admin

07 Aug 2024

1 min 52 sec

Medtech startup SigTuple has secured Rs 33 crore ($4 million) in an extended Series C round led by SIDBI Venture Capital, along with contributions from existing investors such as Endiya Partners and strategic healthcare leaders. This follows a previous $4.3 million Series C round in March 2023, led by Endiya Partners and Accel, bringing the Bengaluru-based company’s total funding to over $40 million.

Founded in 2015 by Apurv Anand, Bharath Cheluvaraju, Rohit Kumar Pandey, and Tathagato Dastidar, SigTuple specializes in AI-driven smart robotic microscopes that automate manual processes in clinical laboratories. Since 2020, the company has focused on its flagship product, AI100, which has seen significant adoption among major diagnostics industry players in India.

The latest funding will support SigTuple’s geographical expansion, product portfolio enhancement, and regulatory clearances. The company has partnered with Horiba Medical for distribution in South Asia and has extended its reach to Southeast Asia, the Middle East, and North Africa, with plans to enter Europe and the Americas. In September 2023, AI100 received US FDA 510(k) approval, making SigTuple the third company globally—and the first in India—to achieve this for AI-assisted digital haematology.